Catalyst Biosciences Inc represents values of innovation, scientific excellence, and dedication to improving patient lives. With a corporate philosophy centered around advanced therapeutic solutions, the company aims to address unmet medical needs in the field of rare and severe diseases. Catalyst Biosciences Inc emphasizes a patient-centric approach, striving to develop novel therapies that provide better outcomes. By leveraging their deep understanding of protease pharmacology, the company focuses on creating next-generation medicines with enhanced safety and efficacy profiles. Through their research and development efforts, Catalyst Biosciences Inc is committed to making a lasting impact in the healthcare industry.

Catalyst Biosciences Inc is primarily present in the United States.

Catalyst Biosciences Inc has achieved several significant milestones. The company successfully developed its proprietary protease technology platform, which enables the engineering of proteases with improved therapeutic properties. Catalyst Biosciences also advanced several programs into clinical development, including CB 2679d/ISU304 for the treatment of hemophilia B and CB 2782 for the potential treatment of dry age-related macular degeneration. Moreover, the company established collaborations with leading pharmaceutical companies, such as Novartis, for the development of novel hemophilia therapies. These achievements demonstrate Catalyst Biosciences' commitment to advancing innovative therapies and its significant progress in the biopharmaceutical field.

Catalyst Biosciences Inc, headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare and life-threatening hematologic and complement-mediated disorders. Founded in 2002 as Targesome Inc, the company was later renamed Catalyst Biosciences in 2006. Catalyst Biosciences has a rich history of scientific innovation and collaboration, aiming to address unmet medical needs. With a dedicated team of experienced researchers and scientists, Catalyst Biosciences is committed to developing safe and effective therapies that can significantly improve the lives of patients dealing with rare diseases.

The main competitors of Catalyst Biosciences Inc in the market include BioMarin Pharmaceutical Inc, Sangamo Therapeutics Inc, and UniQure NV.

Catalyst Biosciences Inc primarily operates in the biotechnology and pharmaceutical industries.

The business model of Catalyst Biosciences Inc. entails the development and commercialization of therapeutics for the treatment of rare and life-threatening diseases. The company focuses on engineering proteases for precision and potent activity in order to address unmet medical needs. Catalyst Biosciences utilizes its proprietary protease platform technology to design novel small molecules and biologics that target specific diseases. By leveraging its expertise in protease engineering, the company aims to provide innovative and effective treatment options for patients in various therapeutic areas, including hematology, rare bleeding disorders, and complement-related diseases.

Det Catalyst Biosciences P/E-forhold er -32,33.

Catalyst Biosciences KUV er 0.

AlleAktien Kvalitetsscore for Catalyst Biosciences er 3/10.

Omsætningen kan i øjeblikket ikke beregnes for Catalyst Biosciences.

Den forventede Catalyst Biosciences indtjening er -1,16 mio. USD.

Catalyst Biosciences Inc is a publicly traded biopharmaceutical company based in Southern California that focuses on developing innovative therapies for severe, rare diseases. The company utilizes its proprietary platform technologies to develop protein therapeutics that regulate hemostasis, treat immune disorders, and specifically target cancer cells. One of the main divisions of Catalyst Biosciences is its hemostasis products, including its Kringle-Designed Targets (KDTs) used in the treatment of hemophilia and other bleeding disorders. These therapeutics are recombinant proteins specifically designed to modulate the body's coagulation cascade before it can lead to uncontrolled bleeding or thrombosis. Catalyst Biosciences also has a successful partnership program with Pfizer Inc. for the development of factor VIIa therapeutics for the treatment of hemophilia patients. Catalyst Biosciences also has a division for precision medicine-based immunotherapeutics. These therapeutics aim to manipulate the immune system to treat inflammatory and autoimmune diseases. The company has developed several proprietary platforms, including CaptiVateTM targeting T and B cells, and TolveraTM enabling next-generation cell-based RNA therapies. Catalyst Biosciences has a strategic partnership with CRISPR Therapeutics for the development of next-generation cure for hemophilia A. Additionally, Catalyst Biosciences is working on cancer therapies based on tumor-specific antibodies. The company has an internal development program, including an anti-CXCL12 antibody aiming to inhibit cancer cell growth in multiple clinical indications. The company also has a partnership with MilliporeSigma for the development of bispecific antibodies for the treatment of cancer. Catalyst Biosciences' business model primarily involves the development and sale of proprietary biological products and technologies. The company has an international patent portfolio and engages in partnerships with other companies to integrate its platform technologies into cell and gene therapy. Catalyst Biosciences receives research, development, licensing, and milestone payments from these partnerships. To expand its operations, Catalyst Biosciences has entered strategic partnerships with other biopharmaceutical companies such as Pfizer, CRISPR Therapeutics, and MilliporeSigma. These partnerships aim to expand and accelerate Catalyst Biosciences' research, development, distribution, and marketing activities. Another important component of Catalyst Biosciences' business model is financing research and development as well as clinical studies. The company has completed several public and private funding rounds to finance its development activities. Catalyst Biosciences has also utilized public funding sources such as Strategic Research Funding Programs (SRFPs) to further develop its platform technologies and products. Overall, Catalyst Biosciences has a unique and diverse business model focused on developing and distributing innovative therapeutic solutions for severe and rare medical needs. With its proprietary technologies and partnerships, the company is able to expand its research and development activities and bring its products to market faster.

Catalyst Biosciences udbetaler et udbytte på 1,43 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Catalyst Biosciences, eller selskabet udbetaler ikke udbytte.

ISIN'en for Catalyst Biosciences er US14888D2080.

WKN for Catalyst Biosciences er A2DLUK.

Tickeren for Catalyst Biosciences er CBIO.

I løbet af de sidste 12 måneder betalte Catalyst Biosciences en dividende på 1,43 USD . Dette svarer til et dividendeudbytte på omkring 8,01 %. For de kommende 12 måneder vil Catalyst Biosciences sandsynligvis betale en dividende på 0,24 USD.

Udbytteafkastet for Catalyst Biosciences er i øjeblikket 8,01 %.

Catalyst Biosciences betaler kvartalsvis udbytte. Dette uddeles i månederne .

Catalyst Biosciences betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0,24 USD. Dette svarer til et dividendeafkast på 1,34 %.

Catalyst Biosciences bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Catalyst Biosciences fra den 12.1.2023 på 0,24 USD, skulle du have haft aktien i din portefølje før ex-datoen den 13.1.2023.

Udbetalingen af det sidste udbytte blev foretaget den 12.1.2023.

I løbet af 2023 udbetalte Catalyst Biosciences 1,43 USD i form af dividender.

Udbytterne fra Catalyst Biosciences udbetales i USD.